Quantum BioPharma

Quantum BioPharma Innovating in Neurodegenerative Disease & Alcohol Health. Creators of unbuzzd™️ & Lucid-MS. Strong Execution. Diversified Treasury. NASDAQ symbol $QNTM

11/21/2025

Lucid-MS is an experimental drug candidate exploring a distinct biological pathway tied to protein citrullination, a process implicated in myelin disruption in Multiple Sclerosis.

By modulating this pathway, Lucid-MS is being studied for its potential to support myelin integrity without suppressing the immune system.

This mechanism differs fundamentally from traditional anti-inflammatory approaches in MS, and preclinical research has reinforced its scientific potential.

$QNTM

Listen to Sim Cha’s Story as she describes how she was affected by the spoofing allegations , we thank every shareholder...
11/17/2025

Listen to Sim Cha’s Story as she describes how she was affected by the spoofing allegations , we thank every shareholder who has shared their story with us.

https://youtu.be/2_yyOCRUlbM?si=zyPdAw_sJMV-WOUU

My ambition to become a successful artist has faded away. I suffered a lot under stress and mental exhaustion - Sim Cha (Belgium) Quantum Biopharma NASDAQ: Q...

11/17/2025

Demyelination is the starting point for understanding Multiple Sclerosis.

When the insulation around axons breaks down, signals slow, misfire, or lose precision — disrupting how neural circuits coordinate together.

Myelin isn’t “supportive tissue.”
It’s core architecture.

It determines how reliably information moves across the nervous system.

Understanding demyelination → understanding MS.

Quantum BioPharma focused on the Neurodegenerative aspect of MS.

$QNTM

11/15/2025

Neurons don’t just carry signals — they depend on insulation.

In a healthy brain, electrical impulses move quickly and accurately because each axon is wrapped in the myelin sheath.

In Multiple Sclerosis, that insulation breaks down.
As myelin deteriorates, communication slows, misfires, or becomes disrupted — driving many MS symptoms.

That’s why the future of MS treatment can’t rely on inflammation control alone.

It must focus on addressing the damage caused by demyelination, specifically the neurodegenerative aspect.

At Quantum BioPharma, Lucid-MS is being developed with a clear mission:

Advancing Science, Saving Lives by Addressing Demyelination and Protecting Neuronal Integrity.

When neurons are protected, stability improves.
When myelin is supported, function has a chance to follow.

That’s the future we’re working toward. Learn More : https://quantumbiopharma.com/lucid-ms

$QNTM

10/23/2025

Most current therapies for Multiple Sclerosis focus on modulating the immune system to reduce inflammatory activity.

Our approach takes a different path: Lucid-MS, a patented new chemical entity small molecule, is designed to target neurodegenerative pathways that contribute to disease progression.

Having successfully completed Phase 1 SAD and MAD clinical studies, Lucid-MS is advancing toward further clinical development.

By focusing on neuronal and myelin integrity, this investigational therapy aims to address biological mechanisms associated with demyelination, representing a distinct, non-immune-modulating approach to

Learn more about Lucid-MS:
https://www.quantumbiopharma.com/lucid-ms

$QNTM

Address

55 University Avenue/Suite 1003
Toronto, ON
M5J2H7

Telephone

+14168548884

Website

Alerts

Be the first to know and let us send you an email when Quantum BioPharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category